Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
Category: GLP-1 RAs (Drug)
-
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
The New York Times – Business: -
Peptides, GLP-1 Drugs and Botox: Needles Are Everywhere Now
The New York Times – On the Runway:Weight-loss drugs, peptides, I.V.F. As sharps migrate out of doctors’ offices, even needle-phobics are willing to embrace shots.
-
Provincetown Bear Week Feels Different in the Age of GLP-1s
The New York Times – Fashion & Style:An annual celebration of bears — gay men on the bigger and hairier side — feels different in the age of GLP-1s.
-
Medicare Coverage for GLP-1 Weight Loss Drugs: Cost, Eligibility and What to Know
The New York Times – Business:What you should know about the federal government’s pilot program offering GLP-1s solely for weight loss.
-
How A.I. Helped One Man (and His Brother) Build a $1.8 Billion Company
The New York Times – Business:Who needs more than two employees when artificial intelligence can do so many corporate tasks? It’s super efficient — and a little bit lonely.
-
Ozempic Is About to Go Generic in India, China and Canada
The New York Times – Business:In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.
-
Weight-Loss Drugs Could Save U.S. Airlines $580 Million Per Year
A study by the financial firm Jefferies highlights a surprising perk for carriers: lower fuel costs as slimmer passengers lighten their aircrafts’ loads.
-
‘Chinese Peptides’ Are the Latest Biohacking Trend in the Tech World
The gray-market drugs flooding Silicon Valley reveal a community that believes it can move faster than the F.D.A.
-
New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trial
The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.
-
U.S. Announces Negotiated Prices for 15 Drugs Under Medicare
The Trump administration said that had the new prices been in effect last year, Medicare would have saved $12 billion, which would have reduced its spending on those drugs by 44 percent.
-
Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials
The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a number of brain diseases.